A Progress Report
暂无分享,去创建一个
[1] J. Lauriello,et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. , 2015, Schizophrenia bulletin.
[2] H. Meltzer,et al. A genetic locus in 7p12.2 associated with treatment resistant schizophrenia , 2014, Schizophrenia Research.
[3] B. Nordestgaard,et al. Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. , 2014, Schizophrenia bulletin.
[4] R. Rosenheck,et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. , 2014, JAMA.
[5] H. Meltzer,et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia , 2014, Schizophrenia Research.
[6] P. Mortensen,et al. Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury. , 2014, The American journal of psychiatry.
[7] F. Gage,et al. Enhancing induced pluripotent stem cell models of schizophrenia. , 2014, JAMA psychiatry.
[8] Godfrey Pearlson,et al. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. , 2014, Schizophrenia bulletin.
[9] P. Mortensen,et al. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. , 2014, The American journal of psychiatry.
[10] E. Spina,et al. Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study , 2014, Journal of clinical psychopharmacology.
[11] B. Bogerts,et al. Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[12] Brian Kirkpatrick,et al. Inflammation and schizophrenia. , 2013, Schizophrenia bulletin.
[13] Patrick D McGorry,et al. The next stage for diagnosis: validity through utility , 2013, World psychiatry : official journal of the World Psychiatric Association.
[14] S. Heckers. What is the core of schizophrenia? , 2013, JAMA psychiatry.
[15] Dimitris Mavridis,et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.
[16] J. Lieberman,et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. , 2013, The American journal of psychiatry.
[17] Hok Pan Yuen,et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. , 2013, JAMA psychiatry.
[18] V. Carli,et al. Childhood trauma and psychosis in a prospective cohort study: cause, effect, and directionality. , 2013, The American journal of psychiatry.
[19] P. Fusar-Poli,et al. Should attenuated psychosis syndrome be included in DSM-5? , 2012, The Lancet.
[20] M. Cannon,et al. Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. , 2011, Schizophrenia bulletin.
[21] W. Fleischhacker,et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. , 2010, The international journal of neuropsychopharmacology.
[22] R. Heinssen,et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. , 2010, The American journal of psychiatry.
[23] P. Buckley,et al. First episode schizophrenia: Considerations on the timing, selection, and duration of antipsychotic therapies , 2009 .
[24] Del D. Miller,et al. Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[25] E. Parellada,et al. Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. , 2014, Journal of psychiatric research.
[26] A. Caspi,et al. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. , 2014, The American journal of psychiatry.
[27] J. Lieberman,et al. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. , 2004, The American journal of psychiatry.